Article Text

Download PDFPDF

315 The relationship between il-10, il-17, il-23 and vitamin d levels, and disease activity of systemic lupus erythematosus
  1. T Senturk1,
  2. BG Cetin2 and
  3. N Aydin3
  1. 1Adnan Menderes University – Medical Faculty, Rheumatology, Aydin, Turkey
  2. 2Adnan Menderes University – Medical Faculty, Internal Medicine, Aydin, Turkey
  3. 3Adnan Menderes University – Medical Faculty, Medical Microbiology, Aydin, Turkey


Background and aims Several cytokines such as IL-10, IL-17, IL-23, and vitamin D have been suspected in the pathogenesis of SLE. However, the association between these cytokines, vitamin D and disease activity is unknown. We aimed to determine the association between IL-10, IL-17, IL-23, vitamin D and SLEDAI score.

Methods We included 40 patients with SLE and 20 healthy controls in the study. Clinical and laboratory parameters and, SLEDAI score were evaluated. Serum IL-10, IL-17 and IL-23 were measured by nephelometry and vitamin D by HPLC. Mann-Whitney U and Kolmogorov-Smirnov test were used for statistical analysis.

Results The level of vitamin D was significantly lower (p=0003), and IL-23 was significantly higher (p=0001) in SLE patients compared to healthy controls. There was no significant difference for IL-10 and IL-17 between both group (p>0,05). However, a significant correlation between vitamin D and disease duration (p=0,02), and between IL-23 and vitamin D (p=0019) were found among SLE patients. Vitamin D levels were correlated with SLEDAI score and IL-23 in patients group.

Conclusions Although there are studies suppporting the role of IL-10 and IL-17 in the pathogenesis of SLE in the literature, there was no significant difference between patients and healthy controls in our study. IL-23 levels were significantly higher, whereas vitamin D levels were significantly lower in SLE patients than in the control group. Also vitamin D levels were negative correlated with duration of disease and IL-23. Levels of IL-23 may be used to evaluated the disease activity, or may be a promising therapeutic approach for SLE patients.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.